Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 1.250
Filtrar
1.
Lancet Microbe ; 5(2): e194-e202, 2024 02.
Artigo em Inglês | MEDLINE | ID: mdl-38101440

RESUMO

Laboratory-acquired infections (LAIs) and accidental pathogen escape from laboratory settings (APELS) are major concerns for the community. A risk-based approach for pathogen research management within a standard biosafety management framework is recommended but is challenging due to reasons such as inconsistency in risk tolerance and perception. Here, we performed a scoping review using publicly available, peer-reviewed journal and media reports of LAIs and instances of APELS between 2000 and 2021. We identified LAIs in 309 individuals in 94 reports for 51 pathogens. Eight fatalities (2·6% of all LAIs) were caused by infection with Neisseria meningitidis (n=3, 37·5%), Yersinia pestis (n=2, 25%), Salmonella enterica serotype Typhimurium (S Typhimurium; n=1, 12·5%), or Ebola virus (n=1, 12·5%) or were due to bovine spongiform encephalopathy (n=1, 12·5%). The top five LAI pathogens were S Typhimurium (n=154, 49·8%), Salmonella enteritidis (n=21, 6·8%), vaccinia virus (n=13, 4·2%), Brucella spp (n=12, 3·9%), and Brucella melitensis (n=11, 3·6%). 16 APELS were reported, including those for Bacillus anthracis, SARS-CoV, and poliovirus (n=3 each, 18·8%); Brucella spp and foot and mouth disease virus (n=2 each, 12·5%); and variola virus, Burkholderia pseudomallei, and influenza virus H5N1 (n=1 each, 6·3%). Continual improvement in LAI and APELS management via their root cause analysis and thorough investigation of such incidents is essential to prevent future occurrences. The results are biased due to the reliance on publicly available information, which emphasises the need for formalised global LAIs and APELS reporting to better understand the frequency of and circumstances surrounding these incidents.


Assuntos
Virus da Influenza A Subtipo H5N1 , Infecção Laboratorial , Yersinia pestis , Animais , Bovinos , Humanos , Salmonella enteritidis , Salmonella typhimurium
2.
Копенгаген; Всемирная организация здравоохранения. Европейское региональное бюро; 2024. (WHO/EURO:2024-8308-48080-73208).
em Russo | WHO IRIS | ID: who-375954

RESUMO

На 37-м совещании Европейской региональной комиссии по сертификации ликвидации полиомиелита (РКС),которое прошло 7-8 сентября 2023 г., были рассмотрены ежегодно обновляемые данные о статусе национальных программ ликвидации полиомиелита в 2022 г. представленные государствами-членами Европейского региона ВОЗ.На основании предоставленных данных РКС сделала вывод, что в 2022 г. в Европейском регионе ВОЗ отсутствовала передача дикого полиовируса (ДПВ), а эпизоды и вспышки, вызванные вакцино-родственным полиовирусом,контролировались надлежащим образом. РКС также пришла к выводу, что в Боснии и Герцеговине и Украине сохраняется высокий риск возникновения устойчивой вспышки полиомиелита в случае завоза ДПВ или возникновения циркулирующего вакцино-родственного полиовируса в первую очередь из-за низкого уровня коллективного иммунитета.


Assuntos
Poliomielite , Programas de Imunização , Contenção de Riscos Biológicos , Infecção Laboratorial , Planejamento Estratégico
4.
Proc Natl Acad Sci U S A ; 120(25): e2219373120, 2023 Jun 20.
Artigo em Inglês | MEDLINE | ID: mdl-37319116

RESUMO

Fungus-growing ants depend on a fungal mutualist that can fall prey to fungal pathogens. This mutualist is cultivated by these ants in structures called fungus gardens. Ants exhibit weeding behaviors that keep their fungus gardens healthy by physically removing compromised pieces. However, how ants detect diseases of their fungus gardens is unknown. Here, we applied the logic of Koch's postulates using environmental fungal community gene sequencing, fungal isolation, and laboratory infection experiments to establish that Trichoderma spp. can act as previously unrecognized pathogens of Trachymyrmex septentrionalis fungus gardens. Our environmental data showed that Trichoderma are the most abundant noncultivar fungi in wild T. septentrionalis fungus gardens. We further determined that metabolites produced by Trichoderma induce an ant weeding response that mirrors their response to live Trichoderma. Combining ant behavioral experiments with bioactivity-guided fractionation and statistical prioritization of metabolites in Trichoderma extracts demonstrated that T. septentrionalis ants weed in response to peptaibols, a specific class of secondary metabolites known to be produced by Trichoderma fungi. Similar assays conducted using purified peptaibols, including the two previously undescribed peptaibols trichokindins VIII and IX, suggested that weeding is likely induced by peptaibols as a class rather than by a single peptaibol metabolite. In addition to their presence in laboratory experiments, we detected peptaibols in wild fungus gardens. Our combination of environmental data and laboratory infection experiments strongly support that peptaibols act as chemical cues of Trichoderma pathogenesis in T. septentrionalis fungus gardens.


Assuntos
Formigas , Infecção Laboratorial , Trichoderma , Animais , Formigas/fisiologia , Jardins , Sinais (Psicologia) , Simbiose , Peptaibols
5.
Emerg Microbes Infect ; 12(1): e2169197, 2023 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-36644859

RESUMO

Omicron and its sublineages are currently predominant and have triggered epidemiological waves of SARS-CoV-2 around the world due to their high transmissibility and strong immune escape ability. Vaccines are key measures to control the COVID-19 burden. Omicron BA.2 caused a large-scale outbreak in Shanghai since March 2022 and resulted in over 0.6 million laboratory-confirmed infections. The vaccine coverage of primary immunization among residents aged 3 years and older in Shanghai exceeded 90%, and inactivated COVID-19 vaccines were mainly delivered. In the context of high vaccine coverage, we conducted a cohort study to assess vaccine effects on reducing the probability of developing symptoms or severity of disease in infections or nonsevere cases. A total of 48,243 eligible participants were included in this study, the majority of whom had asymptomatic infections (31.0%) and mild-to-moderate illness (67.9%). Domestically developed COVID-19 vaccines provide limited protection to prevent asymptomatic infection from developing into mild-to-moderate illness and durable protection to prevent nonsevere illness from progressing to severe illness caused by Omicron BA.2. Partial vaccination fails to provide effective protection in any situation. The level of vaccine effects on disease progression in the elderly over 80 years old was relatively lower compared with other age groups. Our study results added robust evidence for the vaccine performance against Omicron infection and could improve vaccine confidence.


Assuntos
COVID-19 , Infecção Laboratorial , Idoso , Humanos , Idoso de 80 Anos ou mais , Vacinas contra COVID-19 , Estudos de Coortes , COVID-19/epidemiologia , COVID-19/prevenção & controle , SARS-CoV-2 , China/epidemiologia , Vacinação , Infecções Assintomáticas , Surtos de Doenças/prevenção & controle
6.
Clin Infect Dis ; 76(8): 1468-1475, 2023 04 17.
Artigo em Inglês | MEDLINE | ID: mdl-36453094

RESUMO

BACKGROUND: In this study, we compared admission incidence risk and the risk of mortality in the Omicron BA.4/BA.5 wave to previous waves. METHODS: Data from South Africa's SARS-CoV-2 case linelist, national COVID-19 hospital surveillance system, and Electronic Vaccine Data System were linked and analyzed. Wave periods were defined when the country passed a weekly incidence of 30 cases/100 000 population. In-hospital case fatality ratios (CFRs) during the Delta, Omicron BA.1/BA.2, and Omicron BA.4/BA.5 waves were compared using post-imputation random effect multivariable logistic regression models. RESULTS: The CFR was 25.9% (N = 37 538 of 144 778), 10.9% (N = 6123 of 56 384), and 8.2% (N = 1212 of 14 879) in the Delta, Omicron BA.1/BA.2, and Omicron BA.4/BA.5 waves, respectively. After adjusting for age, sex, race, comorbidities, health sector, and province, compared with the Omicron BA.4/BA.5 wave, patients had higher risk of mortality in the Omicron BA.1/BA.2 wave (adjusted odds ratio [aOR], 1.3; 95% confidence interval [CI]: 1.2-1.4) and Delta wave (aOR, 3.0; 95% CI: 2.8-3.2). Being partially vaccinated (aOR, 0.9; 95% CI: .9-.9), fully vaccinated (aOR, 0.6; 95% CI: .6-.7), and boosted (aOR, 0.4; 95% CI: .4-.5) and having prior laboratory-confirmed infection (aOR, 0.4; 95% CI: .3-.4) were associated with reduced risks of mortality. CONCLUSIONS: Overall, admission incidence risk and in-hospital mortality, which had increased progressively in South Africa's first 3 waves, decreased in the fourth Omicron BA.1/BA.2 wave and declined even further in the fifth Omicron BA.4/BA.5 wave. Mortality risk was lower in those with natural infection and vaccination, declining further as the number of vaccine doses increased.


Assuntos
COVID-19 , Infecção Laboratorial , Humanos , África do Sul/epidemiologia , COVID-19/epidemiologia , SARS-CoV-2 , Hospitalização , Hospitais
7.
Copenhagen; World Health Organization. Regional Office for Europe; 2023. (WHO/EURO:2023-8308-48080-71301).
em Inglês | WHO IRIS | ID: who-373871

RESUMO

The thirty-seventh meeting of the European Regional Commission for Certification of Poliomyelitis Eradication (RCC), held on 7–8 September 2023, reviewed annual updates submitted by the Member States of the WHO European Region on the status of the national polio eradication programmes in 2022. The RCC concluded, based on available evidence, that there was no wild poliovirus transmission in the WHO European Region in 2022 and the events and outbreaks caused by vaccine-derived poliovirus were adequately managed. The RCC also concluded that Bosnia and Herzegovina and Ukraine remain at high risk of a sustained polio outbreak in the event of importation of wild poliovirus or the emergence of circulating vaccine-derived poliovirus primarily due to low population immunity.


Assuntos
Poliomielite , Programas de Imunização , Monitoramento Epidemiológico , Contenção de Riscos Biológicos , Infecção Laboratorial , Planejamento Estratégico
8.
Manual de bioseguridad en el laboratorio, cuarta edición y monografías complementarias;
Monografia em Espanhol | WHO IRIS | ID: who-374905
9.
Практическое руководство по биологической безопасности в лабораторных условиях, четвертое издание, и тематические монографии;
Monografia em Russo | WHO IRIS | ID: who-374900
10.
دليل السلامة البيولوجية في المختب ا رت، الطبعة ال ا ربعة، والد ا رسات الإف ا ردية المصاحبة له;
Monografia em Árabe | WHO IRIS | ID: who-374897
11.
Manual de bioseguridad en el laboratorio, cuarta edición y monografías complementarias;
Monografia em Espanhol | WHO IRIS | ID: who-374895
12.
Практическое руководство по биологической безопасности в лабораторных условиях, четвертое издание, и тематические монографии;
Monografia em Russo | WHO IRIS | ID: who-374889
13.
Практическое руководство по биологической безопасности в лабораторных условиях, четвертое издание, и тематические монографии;
Monografia em Russo | WHO IRIS | ID: who-374888
14.
Manual de bioseguridad en el laboratorio, cuarta edición y monografías complementarias;
Monografia em Espanhol | WHO IRIS | ID: who-374887
15.
دليل السلامة البيولوجية في المختب ا رت، الطبعة ال ا ربعة، والد ا رسات الإف ا ردية المصاحبة له;
Monografia em Árabe | WHO IRIS | ID: who-374886
16.
دليل السلامة البيولوجية في المختب ا رت، الطبعة ال ا ربعة، والد ا رسات الإف ا ردية المصاحبة له;
Monografia em Árabe | WHO IRIS | ID: who-374884
17.
Manual de bioseguridad en el laboratorio, cuarta edición y monografías complementarias;
Monografia em Espanhol | WHO IRIS | ID: who-374883
18.
Практическое руководство по биологической безопасности в лабораторных условиях, четвертое издание, и тематические монографии;
Monografia em Russo | WHO IRIS | ID: who-374882
19.
دليل السلامة البيولوجية في المختب ا رت، الطبعة ال ا ربعة، والد ا رسات الإف ا ردية المصاحبة له;
Monografia em Árabe | WHO IRIS | ID: who-374881
20.
Manuel de sécurité biologique en laboratoire, quatrième édition et monographies associées;
Monografia em Francês | WHO IRIS | ID: who-374880
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...